IBO Impact BioMedical Inc.

Subscribe to $IBO

Impact BioMedical Inc.

Subscribe to $IBO

$IBO

Biotechnology: Pharmaceutical Preparations

Health Care

IPO Year: 2024

Exchange: AMEX

Recent Analyst Ratings for Impact BioMedical Inc.

Date	Price Target	Rating	Analyst

See more ratings

Impact BioMedical Inc. Press Releases

Fastest customizable press release news feed in the world

Impact Biomedical Inc. Announcement Stock Activity/Pricing
HOUSTON, March 21, 2025 (GLOBE NEWSWIRE) -- Impact BioMedical Inc. (NYSE:IBO), a pioneering biotechnology company dedicated to discovering, developing, and patenting innovative healthcare solutions, today announced that there has been no material development in its business affairs not previously disclosed or, to its knowledge, any other reason to account for the unusual market action regarding its share price. About Impact BioMedical, Inc.: Impact BioMedical Inc. (NYSE:IBO) discovers, confirms, and patents unique science and technologies which can be developed into new offerings in biopharmaceuticals and consumer healthcare and wellness in collaboration with external partners through re
3/21/25 2:38:33 PM ET
$IBO
Biotechnology: Pharmaceutical Preparations
Health Care
DSS, Inc. Announces Sale of Celios® to Impact BioMedical, Streamlining Portfolio for Strategic Growth
ROCHESTER, N.Y., Feb. 26, 2025 (GLOBE NEWSWIRE) -- DSS, Inc. (NYSE:DSS), a multinational company focused on innovation-driven business models, today announced the sale of its Celios® air purification asset to Impact BioMedical Inc. (NYSE:IBO) in a strategic, all-equity transaction valued at approximately $1.15 million. This divestiture aligns with DSS' ongoing strategy to optimize its portfolio and concentrate on core growth areas. Celios® is a cutting-edge air purification technology featuring a patented three-stage filtration system capable of removing ultrafine particles as small as ten (10) nanometers, helping to improve indoor air quality and mitigate airborne health risks. The sale
2/26/25 8:30:00 AM ET
$DSS
$IBO
Containers/Packaging
Consumer Discretionary
Biotechnology: Pharmaceutical Preparations
Health Care
Impact Biomedical Inc. Announces Acquisition of Celios®, "Protecting People, Plants, and Animals from the World's Most Dangerous Pathogens With Clean-Room Air Quality"
HOUSTON, Feb. 26, 2025 (GLOBE NEWSWIRE) -- Impact BioMedical Inc. (NYSE:IBO), a pioneering biotechnology company dedicated to discovering, developing, and patenting innovative healthcare solutions, today announced the acquisition of Celios®, a pioneering air purification technology company, in a strategic, all equity transaction valued at approximately $1.15 million. This acquisition aligns with Impact Biomedical's focused roll-up strategy, expanding its portfolio with cutting-edge solutions that will generate immediate revenue while reinforcing its commitment to human health and wellness. Celios® brings advanced air purification capability, featuring design, system, and method patents
2/26/25 8:30:00 AM ET
$IBO
Biotechnology: Pharmaceutical Preparations
Health Care
Impact BioMedical Inc. to Present at The Microcap Conference
HOUSTON, Jan. 23, 2025 (GLOBE NEWSWIRE) -- Impact BioMedical Inc. (NYSE:IBO), a pioneering biotechnology company dedicated to discovering, developing, and patenting innovative healthcare solutions, today announced that Frank D. Heuszel, Chief Executive Officer, is pleased to announce his participation in The Microcap Conference 2025, the premier event for growth-focused companies and investors. The conference will take place January 28-30, 2025, at the Borgata Hotel Spa & Casino in Atlantic City, NJ. Mr. Heuszel will deliver a corporate presentation and engage in one-on-one meetings with investors to discuss the company's recent developments, growth strategy, and investment opportunities.
1/23/25 4:30:35 PM ET
$IBO
Biotechnology: Pharmaceutical Preparations
Health Care
Impact BioMedical Inc. Issues Shareholder Letter Highlighting Recent Achievements and Strategic Vision
HOUSTON, Nov. 19, 2024 (GLOBE NEWSWIRE) -- Impact BioMedical Inc. (NYSE:IBO), a pioneering biotechnology company dedicated to discovering, developing, and patenting innovative healthcare solutions, today announced that Frank D. Heuszel, Chairman and Chief Executive Officer of Impact BioMedical Inc., issued the following letter to Impact BioMedical shareholders regarding recent achievements, executional efficiencies and the positive outlook for the Company's future. Dear Impact Biomedical Inc. (IBO) Shareholders, We closed our first quarter as a publicly traded company and wanted to address all current and future stakeholders highlighting our recent achievements, our appreciation for your
11/19/24 8:00:00 AM ET
$IBO
$PRPH
Biotechnology: Pharmaceutical Preparations
Health Care
Impact BioMedical Inc. (NYSE American: IBO) Announces IPO Participation with Strong Support from Partners and Affiliates
HOUSTON, Oct. 07, 2024 (GLOBE NEWSWIRE) -- Impact BioMedical Inc. (NYSE:IBO), a pioneering biotechnology company dedicated to discovering, developing, and patenting innovative healthcare solutions, is pleased to announce the successful completion of its Initial Public Offering (IPO). Notable is that over 30% of the IPO was purchased by existing investors which further demonstrates strong belief in the company and its potential. Frank D. Heuszel, CEO of Impact BioMedical, commented, "The significant participation of our investors underscores their confidence in our mission and the innovative healthcare solutions we are developing. Their support is a testament to the value they see in our w
10/7/24 8:30:00 AM ET
$IBO
Biotechnology: Pharmaceutical Preparations
Health Care
Impact BioMedical Inc. (NYSE: IBO) Announces 3F™ US Patent Issue
HOUSTON, Sept. 26, 2024 (GLOBE NEWSWIRE) -- Impact BioMedical Inc. ("IBO") is pleased to announce that the US Patent and Trademark Office has issued U.S. Patent No. 11,985,973 entitled "Insect Repelling Composition" developed within IBO's 3F™ technology platform. This is in addition to IBO's prior granted U.S. Patent No. 11,246,310. Both patents include compositions and formulations of constituents found in plants and fragrances produced by plants, which, when applied as a natural insect repellent, have the potential to reduce insect landings and bites experienced in an outdoor environment. The terms of U.S. Patents 11,985,973 and 11,246,310 will expire in February 2039 and April 2040, re
9/26/24 8:30:00 AM ET
$IBO
Biotechnology: Pharmaceutical Preparations
Health Care
Impact BioMedical Inc. Introduces Leadership Team to Drive Innovation and Growth
NEW YORK, Sept. 23, 2024 (GLOBE NEWSWIRE) -- Impact BioMedical Inc. (NYSE:IBO), a pioneering biotechnology company dedicated to discovering, developing, and patenting unique healthcare solutions, is pleased to introduce its executive leadership team, poised to lead the company through its next phase of innovation and growth. "We are excited to introduce our exceptional leadership team, which brings together a wealth of experience and a shared vision for driving innovation and growth at Impact BioMedical," said Jason Grady, Impact Biomedical's Director, and Interim CEO of DSS, Inc. "With their expertise and commitment, we are confident in our ability to advance our mission and deliver
9/23/24 8:00:00 AM ET
$IBO
Biotechnology: Pharmaceutical Preparations
Health Care
Impact BioMedical Inc. Announces the Closing of its Initial Public Offering
NEW YORK, Sept. 17, 2024 (GLOBE NEWSWIRE) -- Impact BioMedical Inc. (NYSE:IBO), a company discovering and developing new offerings in human healthcare and wellness, today announced the closing of its previously announced initial public offering of 1,500,000 shares of its common stock at a public offering price of $3.00 per share. The shares began trading on the NYSE American Market on September 16, 2024, under the ticker symbol "IBO". In addition, Impact has granted the underwriters a 45-day option to purchase up to an additional 225,000 shares of its common stock at the public offering price, less underwriting discounts and commissions. All of the shares of common stock are being offere
9/17/24 11:29:05 AM ET
$IBO
Biotechnology: Pharmaceutical Preparations
Health Care
DSS, Inc. Celebrates Impact BioMedical Inc.'s Successful IPO and Proudly Advances Shareholder Value
NEW YORK, Sept. 16, 2024 (GLOBE NEWSWIRE) -- DSS, Inc. (NYSE:DSS), a dedicated supporter and investor in Impact BioMedical Inc. (NYSE:IBO), is delighted to announce the successful pricing of Impact BioMedical's initial public offering (IPO). Impact BioMedical, a trailblazer in advancing human healthcare and wellness solutions, has set its IPO price at $3.00 per share, with an initial offering of 1,500,000 shares. Trading under the ticker symbol "IBO," these shares will begin trading on the NYSE American Market on September 16, 2024. This significant achievement underscores Impact BioMedical's innovative contributions to the healthcare sector and represents a major milestone for DSS. We ar
9/16/24 4:26:04 PM ET
$DSS
$IBO
Containers/Packaging
Consumer Discretionary
Biotechnology: Pharmaceutical Preparations
Health Care

Impact BioMedical Inc.

Recent Analyst Ratings for Impact BioMedical Inc.

Impact BioMedical Inc.

Recent Analyst Ratings for Impact BioMedical Inc.

Impact BioMedical Inc. Press Releases

Fastest customizable press release news feed in the world

Impact Biomedical Inc. Announcement Stock Activity/Pricing

DSS, Inc. Announces Sale of Celios® to Impact BioMedical, Streamlining Portfolio for Strategic Growth

Impact Biomedical Inc. Announces Acquisition of Celios®, "Protecting People, Plants, and Animals from the World's Most Dangerous Pathogens With Clean-Room Air Quality"

Impact BioMedical Inc. to Present at The Microcap Conference

Impact BioMedical Inc. Issues Shareholder Letter Highlighting Recent Achievements and Strategic Vision

Impact BioMedical Inc. (NYSE American: IBO) Announces IPO Participation with Strong Support from Partners and Affiliates

Impact BioMedical Inc. (NYSE: IBO) Announces 3F™ US Patent Issue

Impact BioMedical Inc. Introduces Leadership Team to Drive Innovation and Growth

Impact BioMedical Inc. Announces the Closing of its Initial Public Offering

DSS, Inc. Celebrates Impact BioMedical Inc.'s Successful IPO and Proudly Advances Shareholder Value

Impact BioMedical Inc. SEC Filings

SEC Form 10-Q filed by Impact BioMedical Inc.

Amendment: SEC Form SCHEDULE 13D/A filed by Impact BioMedical Inc.

SEC Form 8-K filed by Impact BioMedical Inc.

SEC Form SCHEDULE 13D filed by Impact BioMedical Inc.

SEC Form 10-K filed by Impact BioMedical Inc.

SEC Form 8-K filed by Impact BioMedical Inc.

Impact BioMedical Inc. filed SEC Form 8-K: Leadership Update

Impact BioMedical Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits

SEC Form S-8 filed by Impact BioMedical Inc.

SEC Form 10-Q filed by Impact BioMedical Inc.

Impact BioMedical Inc. Financials

Live finance-specific insights

Impact Biomedical Inc. Announces Acquisition of Celios®, "Protecting People, Plants, and Animals from the World's Most Dangerous Pathogens With Clean-Room Air Quality"

Impact BioMedical Inc. Insider Purchases

Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

Large owner Dss, Inc. sold $249,408 worth of shares (53,300 units at $4.68) and bought $310 worth of shares (200 units at $1.55) (SEC Form 4)

Chief Executive Officer Heuszel Frank D bought $1,129 worth of shares (500 units at $2.26), increasing direct ownership by 0.52% to 97,344 units (SEC Form 4)

Chief Executive Officer Heuszel Frank D bought $1,305 worth of shares (500 units at $2.61), increasing direct ownership by 0.52% to 96,844 units (SEC Form 4)

Chief Executive Officer Heuszel Frank D bought $2,739 worth of shares (1,050 units at $2.61), increasing direct ownership by 1% to 96,344 units (SEC Form 4)

Large owner Dss, Inc. bought $2,330 worth of shares (1,000 units at $2.33) (SEC Form 4)

Large owner Dss, Inc. bought $153,220 worth of shares (57,800 units at $2.65) (SEC Form 4)

Impact BioMedical Inc. Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

Large owner Dss, Inc. sold $845,013 worth of shares (890,800 units at $0.95), decreasing direct ownership by 85% to 161,100 units (SEC Form 4)

Director Chan Heng Fai Ambrose sold $174,020 worth of shares (351,555 units at $0.49) (SEC Form 4)

Director Chan Heng Fai Ambrose sold $1,122,920 worth of shares (1,689,693 units at $0.66) (SEC Form 4)

Director Chan Heng Fai Ambrose sold $392,800 worth of shares (400,000 units at $0.98) and sold $2,520,021 worth of shares (2,126,918 units at $1.18) (SEC Form 4)

Large owner Dss, Inc. sold $1,950,928 worth of shares (605,620 units at $3.22), decreasing direct ownership by 9% to 1,051,800 units (SEC Form 4)

Large owner Dss, Inc. sold $249,408 worth of shares (53,300 units at $4.68) and bought $310 worth of shares (200 units at $1.55) (SEC Form 4)

Chief Executive Officer Heuszel Frank D bought $1,129 worth of shares (500 units at $2.26), increasing direct ownership by 0.52% to 97,344 units (SEC Form 4)

Chief Executive Officer Heuszel Frank D bought $1,305 worth of shares (500 units at $2.61), increasing direct ownership by 0.52% to 96,844 units (SEC Form 4)

Chief Executive Officer Heuszel Frank D bought $2,739 worth of shares (1,050 units at $2.61), increasing direct ownership by 1% to 96,344 units (SEC Form 4)

Large owner Dss, Inc. sold $17,024 worth of shares (5,700 units at $2.99) (SEC Form 4)